Seattle, WA—A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions. With these new awards, the National Institute of Allergy and Infectious Diseases (NIAID) will increase the number of funded institutions from eight to nine and expand the ability of the VTEUs to conduct research in domestic and international research locations, including resource-poor settings.
Each institution has the potential to receive funding from the NIAID, part of the National Institutes of Health, estimated to be up to $135 million annually over a seven-year period. (During the past seven years, Group Health Research Institute’s VTEU funding averaged $3 million a year.)
“Group Health is the only one of the nine VTEU centers located west of the Rockies—and the only one not at a university medical center,” said Lisa A. Jackson, MD, MPH, principal investigator of the Group Health VTEU and a senior investigator at Group Health Research Institute. “With this new contract, we will be continuing the work we started when we joined the VTEU network in 2007.” The Group Health VTEU is currently focusing on evaluating the new H7N9 influenza strain that caused an outbreak when it was transmitted from birds to people in China last spring. “We will be evaluating a wide range of vaccines in addition to flu vaccines, including smallpox, pneumococcal, and other vaccines, in populations including children, adults, and the elderly,” she added.
Established in 1962, the VTEUs have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure. VTEU investigators have tested vaccines and therapeutics for diseases such as influenza, pneumonia, pertussis, Haemophilus influenzae type B infection, cholera, anthrax, malaria, and tuberculosis. Childhood vaccines and combination vaccines—the delivery of several vaccines through one inoculation—have been and remain an important part of the VTEUs’ research goals.
For example, the network is evaluating the safety of and immune response generated by the pertussis vaccine Tdap in pregnant women and the effect of immunizing expectant mothers on their infants’ immune responses to DTaP, the pertussis vaccine that is routinely administered to children.
In 2001, responding to biodefense concerns, the VTEUs conducted a trial that showed that stockpiled smallpox vaccine could be diluted up to five times and retain its potency, which meant that the original 15.4 million doses were actually enough to protect 77 million people from smallpox infection. More recently, when a new strain of H1N1 influenza emerged in 2009, the VTEUs initiated a series of clinical trials to assess the safety of and immune system response to various dosing regimens of candidate vaccines in healthy adults, elderly people and healthy children. The results of these trials were made available within a few months and helped public health officials and policy makers determine the most appropriate dose of vaccine. Earlier this month, the VTEUs launched two clinical trials to evaluate an investigational vaccine against the H7N9 avian influenza virus that emerged in humans in China earlier this year.
These are the newly awarded VTEU sites and principal investigators (PIs):
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
The National Institutes of Health (NIH), the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.